Alpha-Gal Syndrome Cases Rise, New Treatments
Analysis based on 16 articles · First reported Jun 13, 2026 · Last updated Jun 13, 2026
The approval of Omalizumab by the United States — Food and Drug Administration provides a new treatment option for alpha-gal syndrome, potentially increasing revenue for its manufacturer. The availability of 'GalSafe' pork from Amaroo Hills offers a niche market for consumers with the allergy, impacting the agricultural sector and potentially leading to further innovation in genetically modified food products.
Alpha-gal syndrome is a life-threatening meat allergy triggered by tick bites, specifically from the lone star tick, which introduces alpha-gal sugar into the bloodstream, causing an allergic response. Cases are rising, with an estimated 450,000 Americans affected, due to increased awareness and the expanding habitat of the lone star tick. Symptoms include hives, diarrhea, and in severe cases, anaphylaxis, typically occurring hours after consuming mammalian meat or dairy. Diagnosis involves a blood test for alpha-gal antibodies and symptom review. Treatment primarily involves avoiding mammalian meat, but the United States — Food and Drug Administration recently approved Omalizumab, an injectable drug, to reduce severe allergic reactions. Additionally, genetically modified 'GalSafe' pigs, which do not produce alpha-gal, offer a safe meat alternative from companies like Amaroo Hills. Researchers like Scott Commins and Maria Diuk-Wasser are actively studying the condition and potential new therapies.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard